Markets:

Overview

News

Currencies

International

Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

603.71 +0.81 (+0.13%)

Delayed Quote Updated: 3:14 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

1 Healthcare Stock with Solid Fundamentals and 2 to Ignore

March 28, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

This Kraft Heinz Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

March 24, 2025

Via Benzinga

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

March 21, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)

March 18, 2025

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.

Via StockStory

$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today ↗

October 22, 2024

Via Benzinga

Insights Ahead: Medpace Hldgs's Quarterly Earnings ↗

October 18, 2024

Via Benzinga

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

March 11, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...

Via StockStory

Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

March 05, 2025

Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.

Via StockStory

2 Reasons to Watch MEDP and 1 to Stay Cautious

March 03, 2025

Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period.

Via StockStory

Topics Stocks

Why Medpace (MEDP) Shares Are Trading Lower Today

February 11, 2025

Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and...

Via StockStory

Exploring Medpace Hldgs's Earnings Expectations ↗

October 18, 2024

Via Benzinga

Earnings Preview For Medpace Hldgs ↗

October 18, 2024

Via Benzinga

Examining the Future: Medpace Hldgs's Earnings Outlook ↗

October 18, 2024

Via Benzinga

Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 11, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's after-hours session. ↗

February 10, 2025

The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Medpace Stock Falls On Q4 Earnings: The Details ↗

February 10, 2025

Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.

Via Benzinga

Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops

February 10, 2025

Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s...

Via StockStory

A Look at Medpace Hldgs's Upcoming Earnings Report ↗

October 18, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Medpace Hldgs ↗

October 14, 2024

Via Benzinga

Looking Into Medpace Hldgs's Recent Short Interest ↗

October 01, 2024

Via Benzinga

Earnings Scheduled For February 10, 2025 ↗

February 10, 2025

Via Benzinga

Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect

February 09, 2025

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect.

Via StockStory

10 Health Care Stocks Whale Activity In Today's Session ↗

December 05, 2024

Via Benzinga

This McDonald's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

October 23, 2024

Via Benzinga

Why Is Medpace Stock Diving On Tuesday? ↗

October 22, 2024

Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast.

Via Benzinga

How Medpace Just Blew Up Expectations For Double-Digit Sales Growth In 2025 ↗

October 22, 2024

The contract research organization missed bookings expectations, but didn't offer into any insight into the impact for 2025.

Via Investor's Business Daily

Sherwin-Williams Posts Weak Results, Joins Logitech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 22, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 22, 2024

Via Benzinga

Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗

October 22, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 21, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.